Study on the Impact of a Modified Mediterranean Diet, in Patients With Colorectal Cancer Undergoing Active Medical Oncology Treatment

Launched by AZIENDA SOCIO SANITARIA DELLA BRIANZA · Jan 24, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how a Modified Mediterranean Diet may affect the gut bacteria in patients with metastatic colorectal cancer who are receiving chemotherapy, with or without additional targeted treatments. The goal is to see if this special diet can help the good bacteria in the gut thrive, which might improve the body's ability to cope with cancer treatment and enhance the patients' quality of life. The researchers will compare the gut bacteria of participants following this diet to those on a standard Western diet.

To participate in this study, individuals must be at least 18 years old, have a confirmed diagnosis of metastatic colorectal cancer, and be starting their first round of chemotherapy. They should also be in good health with a performance status score of 0 or 1, meaning they can carry out normal activities. Participants will need to agree to take part in the study by providing written consent. Throughout the trial, they can expect to receive support and monitoring related to their diet and health, helping to better understand the relationship between diet, gut bacteria, and cancer treatment outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eastern Cooperative Oncology Group performance status (ECOG): 0 or 1;
• • Age ≥ 18;
• • Diagnosis of metastatic colorectal cancer, documented histologically and radiologically according to RECIST 1:1 criteria;
• • 1st line chemotherapy treatment +/- biological agent (anti-EGFR, anti-VEGF);
• • MUST score 0/1;
• • Written informed consent.
• Exclusion Criteria:
• • Previous oncological medical therapies;
• • Indication for parenteral and/or enteral nutrition;
• • MUST score \> 2.